InterPAD - DETAILS

2-Methoxyestradiol, 362-07-2, Panzem, 2-Methoxyestradiol-17beta, 2-Hydroxyestradol 2-methyl ether, 2-ME2, 2ME2, 2-MeOE2, Estradiol, 2-methoxy-, 2-Methoxyestradiol (2-MeOE2), 2-methoxyoestradiol, 2-Hydroxyestradiol 2-methyl ether, 2-methoxy-17beta-estradiol, (17beta)-2-Methoxyestra-1,3,5(10)-triene-3,17-diol, NSC-659853, 2-Methoxyestra-1,3,5(10)-triene-3,17beta-diol, 2-Methoxy-estradiol, 2-Methoxy-beta-estradiol, MLS000028819, 6I2QW73SR5, CHEMBL299613, (8R,9S,13S,14S,17S)-2-methoxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol, CHEBI:28955, Estra-1,3,5(10)-triene-3,17-diol, 2-methoxy-, (17beta)-, Panzem NCD, 1,3,5(10)-ESTRATRIEN-2,3,17-BETA-TRIOL 2-METHYL ETHER, 2-methoxy-estra-1,3,5(10)-triene-3,17beta-diol, MFCD00010489, Estra-1,3,5(10)-triene-3,17beta-diol, 2-methoxy-, SMR000058478, 2-Methoxy 17b-Estradiol, 2-Methoxy 17beta-Estradiol, (17beta)-2-methoxyestra-1(10),2,4-triene-3,17-diol, PulmoLAR, 2-Methoxy-.beta.-estradiol, NSC 659853, UNII-6I2QW73SR5, CCRIS 9405, 1lhw, Opera_ID_634, Estra-1,3,5(10)-triene-3,17-diol, 2-methoxy-, (17b)-, 2-Methoxyestradiol Powder, 2-Methoxyestradiol, powder, 2-Methoxy 17?-Estradiol, M 6383, SCHEMBL8796, 2-MeO-E2, Lopac0_000739, (8R,9S,13S,14S,17S)-2-methoxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol, MLS001076279, MLS006010142, 1,3,5(10)-Estratriene-2,3,17-triol 2-methyl ether, DTXSID3040938, GTPL12058, HMS2230L22, HMS3262C20, HMS3412H22, HMS3676H22, BCP02076, 2-METHOXYESTRADIOL [WHO-DD], 2-METHOXYOESTRADIOL [MART.], Tox21_500739, BDBM50060957, LMST02010035, s1233, AKOS015901723, 2-Methoxyestradiol, analytical standard, BCP9000109, CCG-204824, CS-0176, DB02342, LP00739, SDCCGSBI-0050717.P002, SMP2_000045, NCGC00094082-03, NCGC00094082-04, NCGC00094082-13, NCGC00261424-01, AC-32086, AS-19175, BP-25393, HY-12033, EU-0100739, FT-0612836, M2530, NS00115961, C05302, C74863, AB00639611-09, AB00639611_10, SR-01000076000, 2-methoxy-1,3,5 (10)-estratriene-3,17beta-diol, 2-Methoxyestra-1,3,5(10)-triene-3,17-diol #, Q4596897, SR-01000076000-1, BRD-K44408410-001-20-0, (17?)-2-Methoxyestra-1(10),2,4-triene-3,17-diol, 17beta-2-methoxyestra-1,3,5(10)-triene-3,17-diol, Estra-1,3,5(10)-triene-3,17.beta.-diol, 2-methoxy-, estra-1(10),2,4-triene-3,17-diol, 2-methoxy-, (17beta)-, (14beta,17beta)-2-methoxyestra-1(10),2,4-triene-3,17-diol, (17.BETA.)-2-METHOXYESTRA-1,3,5(10)-TRIENE-3,17-DIOL, B3C40B85-1733-48FE-8418-A39011910D19, Estra-1,3,5(10)-triene-3,17-diol, 2-methoxy-, (17.beta.)-

Name	2-methoxyestradiol
PubChem CID	66414
Molecular Weight	302.4g/mol
Synonyms	2-Methoxyestradiol, 362-07-2, Panzem, 2-Methoxyestradiol-17beta, 2-Hydroxyestradol 2-methyl ether, 2-ME2, 2ME2, 2-MeOE2, Estradiol, 2-methoxy-, 2-Methoxyestradiol (2-MeOE2), 2-methoxyoestradiol, 2-Hydroxyestradiol 2-methyl ether, 2-methoxy-17beta-estradiol, (17beta)-2-Methoxyestra-1,3,5(10)-triene-3,17-diol, NSC-659853, 2-Methoxyestra-1,3,5(10)-triene-3,17beta-diol, 2-Methoxy-estradiol, 2-Methoxy-beta-estradiol, MLS000028819, 6I2QW73SR5, CHEMBL299613, (8R,9S,13S,14S,17S)-2-methoxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol, CHEBI:28955, Estra-1,3,5(10)-triene-3,17-diol, 2-methoxy-, (17beta)-, Panzem NCD, 1,3,5(10)-ESTRATRIEN-2,3,17-BETA-TRIOL 2-METHYL ETHER, 2-methoxy-estra-1,3,5(10)-triene-3,17beta-diol, MFCD00010489, Estra-1,3,5(10)-triene-3,17beta-diol, 2-methoxy-, SMR000058478, 2-Methoxy 17b-Estradiol, 2-Methoxy 17beta-Estradiol, (17beta)-2-methoxyestra-1(10),2,4-triene-3,17-diol, PulmoLAR, 2-Methoxy-.beta.-estradiol, NSC 659853, UNII-6I2QW73SR5, CCRIS 9405, 1lhw, Opera_ID_634, Estra-1,3,5(10)-triene-3,17-diol, 2-methoxy-, (17b)-, 2-Methoxyestradiol Powder, 2-Methoxyestradiol, powder, 2-Methoxy 17?-Estradiol, M 6383, SCHEMBL8796, 2-MeO-E2, Lopac0_000739, (8R,9S,13S,14S,17S)-2-methoxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol, MLS001076279, MLS006010142, 1,3,5(10)-Estratriene-2,3,17-triol 2-methyl ether, DTXSID3040938, GTPL12058, HMS2230L22, HMS3262C20, HMS3412H22, HMS3676H22, BCP02076, 2-METHOXYESTRADIOL [WHO-DD], 2-METHOXYOESTRADIOL [MART.], Tox21_500739, BDBM50060957, LMST02010035, s1233, AKOS015901723, 2-Methoxyestradiol, analytical standard, BCP9000109, CCG-204824, CS-0176, DB02342, LP00739, SDCCGSBI-0050717.P002, SMP2_000045, NCGC00094082-03, NCGC00094082-04, NCGC00094082-13, NCGC00261424-01, AC-32086, AS-19175, BP-25393, HY-12033, EU-0100739, FT-0612836, M2530, NS00115961, C05302, C74863, AB00639611-09, AB00639611_10, SR-01000076000, 2-methoxy-1,3,5 (10)-estratriene-3,17beta-diol, 2-Methoxyestra-1,3,5(10)-triene-3,17-diol #, Q4596897, SR-01000076000-1, BRD-K44408410-001-20-0, (17?)-2-Methoxyestra-1(10),2,4-triene-3,17-diol, 17beta-2-methoxyestra-1,3,5(10)-triene-3,17-diol, Estra-1,3,5(10)-triene-3,17.beta.-diol, 2-methoxy-, estra-1(10),2,4-triene-3,17-diol, 2-methoxy-, (17beta)-, (14beta,17beta)-2-methoxyestra-1(10),2,4-triene-3,17-diol, (17.BETA.)-2-METHOXYESTRA-1,3,5(10)-TRIENE-3,17-DIOL, B3C40B85-1733-48FE-8418-A39011910D19, Estra-1,3,5(10)-triene-3,17-diol, 2-methoxy-, (17.beta.)-
Drug Type	Small molecule
Formula	C₁₉H₂₆O₃
SMILES	CC12CCC3C(C1CCC2O)CCC4=CC(=C(C=C34)OC)O
InChI	1S/C19H26O3/c1-19-8-7-12-13(15(19)5-6-18(19)21)4-3-11-9-16(20)17(22-2)10-14(11)12/h9-10,12-13,15,18,20-21H,3-8H2,1-2H3/t12-,13+,15-,18-,19-/m0/s1
InChIKey	CQOQDQWUFQDJMK-SSTWWWIQSA-N
CAS Number	362-07-2
ChEMBL ID	CHEMBL299613
ChEBI ID	CHEBI:28955
TTD ID	D06NYA
Drug Bank ID	DB02342
KEGG ID	C05302
Toxicity	Organism	Test Type	Route(Dose)
	rat	LD50	intraperitoneal(165 mg/kg)
	mouse	LD50	intraperitoneal(254 mg/kg)
	rat	LD50	oral(322 mg/kg)
Structure			Download 2D MOL 3D MOL

Pair Name	Eugenol, 2-methoxyestradiol
Partner Name	Eugenol
Disease Info	[ICD-11: 2C82]	Prostate cancer		Investigative
Biological Phenomena	Induction-->Blockade of cell cycle in G2/M phase
Gene Regulation	Up-regulation	Expression	BAX	hsa581
Gene Regulation	Down-regulation	Expression	BCL2	hsa596
In Vitro Model	LNCaP	Prostate carcinoma	Homo sapiens (Human)	CVCL_0395
	PC-3	Prostate carcinoma	Homo sapiens (Human)	CVCL_0035
	DU145	Prostate carcinoma	Homo sapiens (Human)	CVCL_0105
Result	Combining these agents may allow ameliorating any adverse effects of either 2-ME(2) or eugenol alone by reducing their individual concentrations should these two agents be developed for human use.